TherapeuticsMD
TXMD
123 hedge funds and large institutions have $1.36B invested in TherapeuticsMD in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 18 closing their positions.
334% more call options, than puts
Call options by funds: $4.97M | Put options by funds: $1.14M
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
40% more capital invested
Capital invested by funds: $973M → $1.36B (+$389M)
0.07% more ownership
Funds ownership: 1.56% → 1.63% (+0.07%)
4% less funds holding
Funds holding: 128 → 123 (-5)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$27.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.7M |
| 3 |
Bank of New York Mellon
New York
|
+$24.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$10.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.2M |
| 2 |
Millennium Management
New York
|
-$6.15M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.68M |
| 4 |
GH
GAM Holding
Zurich,
Switzerland
|
-$3.58M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.65M |
TXMD Hedge Fund Activity: Q2 2016 in Review
123 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2016, worth a combined $1.36B — up 40% from $973M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TXMD and 15 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 51 added.
The largest buyer was JP Morgan Chase, adding an estimated $27.3M. The largest seller was Wellington Management Group, cutting an estimated $26.2M.
- 123 institutional investors held TherapeuticsMD (TXMD) as of Q2 2016, down from 128 in Q1 2016.
- Funds reported $1.36B of TherapeuticsMD stock for Q2 2016, up 40% quarter-over-quarter.
- 15 funds opened new TherapeuticsMD positions in Q2 2016 and 18 closed out, a net change of -3 holders.
- The largest TherapeuticsMD buyer in Q2 2016 was JP Morgan Chase, an estimated $27.3M added.
- The largest TherapeuticsMD seller in Q2 2016 was Wellington Management Group, an estimated $26.2M sold.
Based on aggregated 13F filings for Q2 2016.